Table 2.
Agent | Mechanism of Action | Side Effects |
---|---|---|
Bisphosponates (BPs) | Inhibition of bone demineralization by the interruption of enhanced osteolysis and tumor growth [16] | Fever, arthralgia, myalgia, anemia, nausea and peripheral edema. Osteonecrosis of the jaw (rare, difficult to establish casative evidence) [17] |
Tetracyclines | Inhibition of matrix metalloproteinases (MMPs) involved in bone metastasis [17] | Dose-limiting toxicity e.g., fatigue and nausea, development of resistance [18] Generally well tolerated in adults |
Denosumab | Inhibition of RANKL which prevents the development of osteoclasts | Similar to those exhibited by BPs, but reversible after treatment interruption [15] |
Cabozantinib | Inhibition of vascular endothelial growth factor receptor-2 (VEGFR2), MET, KIT and mutationally activated RET [15] | Fatigue, diarrhea and palmar-plantar erythrodysesthesia syndrome [19] |
Radionuclide therapy | Systemic administration of radioisotopes, but the mechanism of pain relief is uncertain [20] | Myelosuppression and pain flare [15] |
Ablation | Use of chemical agents (ethanol, acetic acid) or local deposition of some form of energy (e.g., for radiofrequency and cryoablation) to destroy tumor cells [21] | Neurologic injuries, neuropathic pain and infection in the treatment area (especially for radiofrequency and cryoablation) [22] |